The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)
Abstract
A tutorial review showcasing how peptide–drug conjugates can offer the versatility needed for a successful drug discovery approach, their problems and future opportunities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this strategy has several drawbacks that usually arise due to their limited bioavailability and specificity [115,116].”
From The Role of RhoH in TCR Signalling and Its Involvement in Diseases (2021) · cites this paper as [116]
Experimental — accuracy not yet measuredIn the citing paper
“although peptide drugs can enter cells to restore p53 function, it is difficult to maintain stability and function after entering the human body.505,506”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [505]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Heinis, C., Rutherford, T., Freund, S., & Winter, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.184 · Cited by 743
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Cleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 652
Self-citationAdvances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Highly Efficient Synthesis of Covalently Cross-Linked Peptide Helices by Ring-Closing Metathesis
Blackwell, H. E., & Grubbs, R. H. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981217)37:23<3281::aid-anie3281>3.0.co;2-v · Cited by 558
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability
Lamson, N. G., Berger, A., Fein, K. C., & Whitehead, K. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0465-5 · Cited by 296
Giles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garcia-Manero, G., Waddelow, T. A., David, C. L., Phan, A. T., Colburn, D. E., Rashid, A., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u · Cited by 283
Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.
Harris, A. G. (1994) · Gut · doi:10.1136/gut.35.3_suppl.s1 · Cited by 266
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Hoppenz, P., Els-Heindl, S., & Beck-Sickinger, A. G. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00571 · Cited by 242
Improving oral bioavailability of cyclic peptides by N-methylation
Räder, A. F. B., Reichart, F., Weinmüller, M., & Kessler, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.031 · Cited by 215
Li, N., Li, N., Yi, Q., Luo, K., Guo, C., Pan, D., & Gu, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.07.059 · Cited by 209
Kalimuthu, K., Lubin, B.-C., Bazylevich, A., Gellerman, G., Shpilberg, O., Luboshits, G., & Firer, M. A. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0362-1 · Cited by 181
Protease‐activated prodrugs: strategies, challenges, and future directions
Poreba, M. (2020) · The FEBS Journal · doi:10.1111/febs.15227 · Cited by 160
Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 158
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist
Bucheit, J. D., Pamulapati, L. G., Carter, N., Malloy, K., Dixon, D. L., & Sisson, E. M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0185 · Cited by 156
Peptide‐mediated targeted drug delivery
Majumdar, S., & Siahaan, T. J. (2010) · Medicinal Research Reviews · doi:10.1002/med.20225 · Cited by 152
Oral Administration of Peptide‐Based Drugs: Beyond Lipinski's Rule
dos Santos, G. B., Ganesan, A., & Emery, F. D. S. (2016) · ChemMedChem · doi:10.1002/cmdc.201600288 · Cited by 152
Rotin, D., Robinson, B., & Tannock, I. F. (1986) · PubMed · Cited by 134
Designer Peptide and Protein Dendrimers: A Cross-Sectional Analysis
Sapra, R., Verma, R. P., Maurya, G. P., Dhawan, S., Babu, J., & Haridas, V. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00153 · Cited by 131
Qi, X., Shi, Gao, Q., & Xiang, ■. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30104 · Cited by 125
Hock, M. B., Thudium, K. E., Carrasco‐Triguero, M., & Schwabe, N. F. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9684-6 · Cited by 106
Stapled RGD Peptide Enables Glioma-Targeted Drug Delivery by Overcoming Multiple Barriers
Ruan, H., Chen, X., Xie, C., Li, B., Man, Y. M., Liu, Y., Zhang, M., Zhang, X., Zhan, C., Lu, W., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03682 · Cited by 90
Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads
Mudd, G., Brown, A. N., Chen, L., Rietschoten, K. V., Watcham, S. M., Teufel, D. P., Pavan, S., Lani, R., Huxley, P., & Bennett, G. S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02129 · Cited by 83
Sulfatase-cleavable linkers for antibody-drug conjugates
Bargh, J. D., Walsh, S. J., Isidro‐Llobet, A., Omarjee, S., Carroll, J. S., & Spring, D. R. (2020) · Chemical Science · doi:10.1039/c9sc06410a · Cited by 80
Self-citationYou, Y., Xu, Z., & Chen, Y. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1435746 · Cited by 65
Hadar, J., Skidmore, S., Garner, J., Park, H., Park, K., Wang, Y., Qin, B., & Jiang, X. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.039 · Cited by 60
Advances in PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY
(2023) · Advances in protein chemistry and structural biology · doi:10.1016/s1876-1623(23)00069-x · Cited by 60
Peptide‐Modified Dendrimer Nanoparticles for Targeted Therapy of Colorectal Cancer
Carvalho, M. R., Carvalho, C. R., Maia, F. R., Caballero, D., Kundu, S. C., Reis, R. L., & Oliveira, J. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900132 · Cited by 58
Sun, Y., Liang, Y., Dai, W., He, B., Zhang, H., Wang, X., Wang, J., Huang, S., & Zhang, Q. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00770 · Cited by 57
Optimization of Protein and Peptide Drugs Based on the Mechanisms of Kidney Clearance
Wu, H., & Huang, J. (2018) · Protein and Peptide Letters · doi:10.2174/0929866525666180530122835 · Cited by 49
Tripodi, A. A. P., Ranđelović, I., Biri‐Kovács, B., Szeder, B., Mező, G., & Tóvári, J. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00773-3 · Cited by 36
Studies of Poly(ethylene glycol) Modification of HM-3 Polypeptides
Zhou, K., Zheng, X., Xu, H., Zhang, J., Chen, Y., Xi, T., & Feng, T. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900070r · Cited by 28
Nishimura, Y., Francis, J. N., Donau, O. K., Jesteadt, E., Sadjadpour, R., Smith, A. R., Seaman, M. S., Welch, B. D., Martin, M. A., & Kay, M. S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009700117 · Cited by 26
Research works printed but not linked: 4
- He, 2019, Asian J. Pharm. Sci., 15, 19
- Theratechnologies Inc., New Data Show Theratechnologies’ SORT1+ Technology Is Effective in Many Treatment-Resistant Cancers, https://www.theratech.com/wp-content/uploads/2020/06/Press-release-AACR-June-22-EN-FINAL.pdf , accessed 11 September 2020
- Shi, 2012, Int. J. Nanomed., 7, 1613
- Rotin, 1986, Cancer Res., 46, 2821
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Antibody–drug conjugates: Recent advances in payloads
Wang, Z., Li, H., Gou, L., Li, W., & Wang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.015 · Cited by 264
The Role of RhoH in TCR Signalling and Its Involvement in Diseases
Ahmad Mokhtar, A. M., Hashim, I. F., Mohd Zaini Makhtar, M., Salikin, N. H., & Amin-Nordin, S. (2021) · Cells · doi:10.3390/cells10040950 · Cited by 25
Metadata
- Authors
- Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R.
- Affiliations
- Department of Chemistry
- Oncology R&D
- Medicinal Chemistry
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2021
- Volume
- 50
- Issue
- 3
- Pages
- 1480-1494
- ISSN
- 0306-0012
- 1460-4744
- Cited by
- 414
- References
- 40
- Language
- en
- Funders
- Engineering and Physical Sciences Research Council (G102522)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.